Referred to the Committee on Science, Space, and Technology, and in addition to the Committees on Foreign Affairs, Agriculture, Energy and Commerce, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
H.R. 2756 establishes a coordinated federal effort to advance biotechnology research, development, and commercialization by creating a National Biotechnology Coordination Office—led by a Director and supported by an interagency committee of 14 federal departments—to streamline regulations, coordinate research, and support the biotech industry. The bill provides $22–35 million annually from 2026 through 2030 to fund the Office's operations and staff, while requiring the creation of a federal biotechnology website consolidating funding opportunities and regulatory guidance within 540 days. The Office will submit annual reports to Congress on federal biotechnology spending and develop comprehensive national strategies every five years to assess U.S. competitiveness, commercialization barriers, and infrastructure needs. Key priorities include building biological data infrastructure with privacy protections, supporting private-sector commercialization through federal programs and testbeds, establishing clear regulatory approval pathways, strengthening biosafety and biosecurity frameworks, developing the biotechnology workforce, and expanding international partnerships on standards and market access.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.